Vitrolife AB (publ)

OM:VITR Stock Report

Market Cap: SEK 28.2b

Vitrolife Valuation

Is VITR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VITR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 251.50
Fair Value
17.3% undervalued intrinsic discount
4
Number of Analysts

Below Fair Value: VITR (SEK208) is trading below our estimate of fair value (SEK251.5)

Significantly Below Fair Value: VITR is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VITR?

Key metric: As VITR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VITR. This is calculated by dividing VITR's market cap by their current revenue.
What is VITR's PS Ratio?
PS Ratio7.9x
SalesSEK 3.56b
Market CapSEK 28.16b

Price to Sales Ratio vs Peers

How does VITR's PS Ratio compare to its peers?

The above table shows the PS ratio for VITR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average12.4x
BONEX Bonesupport Holding
30.2x33.8%SEK 24.6b
BIOG B BioGaia
8.5x11.2%SEK 11.5b
SOBI Swedish Orphan Biovitrum
4.5x9.1%SEK 113.6b
PROB Probi
6.3x5.3%SEK 4.0b
VITR Vitrolife
7.9x8.3%SEK 28.2b

Price-To-Sales vs Peers: VITR is good value based on its Price-To-Sales Ratio (7.9x) compared to the peer average (12.4x).

Price to Sales Ratio vs Industry

How does VITR's PS Ratio compare vs other companies in the SE Biotechs Industry?

9 CompaniesPrice / SalesEstimated GrowthMarket Cap
XBRANE Xbrane Biopharma
1.3x58.0%US$23.54m
SPRINT Sprint Bioscience
1.9x27.6%US$10.44m
GEAN Genetic Analysis
1.2xn/aUS$2.10m
LPGO Lipigon Pharmaceuticals
2.3x127.1%US$1.86m
VITR 7.9xIndustry Avg. 11.0xNo. of Companies9PS01224364860+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VITR is good value based on its Price-To-Sales Ratio (7.9x) compared to the Swedish Biotechs industry average (11x).

Price to Sales Ratio vs Fair Ratio

What is VITR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VITR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.9x
Fair PS Ratio4.1x

Price-To-Sales vs Fair Ratio: VITR is expensive based on its Price-To-Sales Ratio (7.9x) compared to the estimated Fair Price-To-Sales Ratio (4.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VITR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 208.00
SEK 272.00
+30.8%
2.9%SEK 280.00SEK 260.00n/a4
Jan ’26SEK 215.00
SEK 273.33
+27.1%
3.4%SEK 280.00SEK 260.00n/a3
Dec ’25SEK 224.80
SEK 273.33
+21.6%
3.4%SEK 280.00SEK 260.00n/a3
Nov ’25SEK 231.40
SEK 271.67
+17.4%
3.1%SEK 280.00SEK 260.00n/a3
Oct ’25SEK 251.20
SEK 271.67
+8.1%
3.1%SEK 280.00SEK 260.00n/a3
Sep ’25SEK 247.00
SEK 261.67
+5.9%
3.9%SEK 275.00SEK 250.00n/a3
Aug ’25SEK 231.20
SEK 261.67
+13.2%
3.9%SEK 275.00SEK 250.00n/a3
Jul ’25SEK 172.90
SEK 231.67
+34.0%
10.3%SEK 265.00SEK 210.00n/a3
Jun ’25SEK 184.70
SEK 231.67
+25.4%
10.3%SEK 265.00SEK 210.00n/a3
May ’25SEK 166.30
SEK 231.67
+39.3%
10.3%SEK 265.00SEK 210.00n/a3
Apr ’25SEK 201.00
SEK 248.33
+23.5%
6.6%SEK 270.00SEK 230.00n/a3
Mar ’25SEK 184.00
SEK 248.33
+35.0%
6.6%SEK 270.00SEK 230.00n/a3
Feb ’25SEK 166.10
SEK 241.67
+45.5%
8.7%SEK 270.00SEK 220.00n/a3
Jan ’25SEK 194.70
SEK 255.00
+31.0%
7.3%SEK 280.00SEK 235.00SEK 215.003
Dec ’24SEK 182.30
SEK 250.00
+37.1%
9.8%SEK 280.00SEK 220.00SEK 224.803
Nov ’24SEK 144.60
SEK 256.67
+77.5%
12.9%SEK 300.00SEK 220.00SEK 231.403
Oct ’24SEK 147.00
SEK 281.67
+91.6%
5.1%SEK 300.00SEK 265.00SEK 251.203
Sep ’24SEK 150.40
SEK 281.67
+87.3%
5.1%SEK 300.00SEK 265.00SEK 247.003
Aug ’24SEK 164.20
SEK 281.67
+71.5%
5.1%SEK 300.00SEK 265.00SEK 231.203
Jul ’24SEK 209.40
SEK 315.00
+50.4%
4.7%SEK 330.00SEK 295.00SEK 172.903
Jun ’24SEK 220.20
SEK 321.67
+46.1%
6.0%SEK 340.00SEK 295.00SEK 184.703
May ’24SEK 230.40
SEK 321.67
+39.6%
6.0%SEK 340.00SEK 295.00SEK 166.303
Apr ’24SEK 215.20
SEK 318.33
+47.9%
7.5%SEK 340.00SEK 285.00SEK 201.003
Mar ’24SEK 213.00
SEK 318.33
+49.5%
7.5%SEK 340.00SEK 285.00SEK 184.003
Feb ’24SEK 229.80
SEK 335.00
+45.8%
1.5%SEK 340.00SEK 330.00SEK 166.102
Jan ’24SEK 186.20
SEK 335.00
+79.9%
1.5%SEK 340.00SEK 330.00SEK 194.702
Analyst Price Target
Consensus Narrative from 4 Analysts
SEK 272.00
Fair Value
23.5% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/17 03:21
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vitrolife AB (publ) is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kallum TitchmarshBofA Global Research
Kallum TitchmarshBofA Global Research